First patient treated in the U.S. Initial enrollment planned for the U.S., Japan, and Taiwan, with further expansion to additional countries and regions SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision,...
Hence then, the article about rakuten medical announces initiation of global phase 3 trial of asp 1929 photoimmunotherapy in combination with pembrolizumab for first line recurrent head and neck cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Rakuten Medical Announces Initiation of Global Phase 3 Trial of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for First-Line Recurrent Head and Neck Cancer )
Also on site :
- Islamic State claims Niger airport attack
- ‘Redline’: Global NGOs working in Gaza defy Israel’s threats after MSF ban
- The World’s Tallest Hotel Has Officially Opened in Dubai